Urinary Epidermal Growth Factor in Cancer Patients
Author Information
Author(s): A.-L. Mattila, I. Saario, L. Viinikka, O. Ylikorkala, J. Perheentupa
Primary Institution: University of Helsinki
Hypothesis
Does urinary epidermal growth factor (U-irEGF) concentration differ between cancer patients and healthy controls?
Conclusion
Urinary EGF concentration was found to be higher in female cancer patients, particularly those with endometrial carcinoma.
Supporting Evidence
- U-irEGF concentrations were higher in female cancer patients compared to healthy controls.
- Only women with endometrial carcinoma showed significantly elevated U-irEGF levels.
- The study included a diverse range of malignancies, including breast and ovarian cancers.
Takeaway
The study looked at a substance in urine that might be linked to cancer, and found that women with certain types of cancer had more of it than healthy women.
Methodology
Urine samples were collected from 97 cancer patients and compared to age- and sex-matched healthy controls, measuring U-irEGF levels using radioimmunoassay.
Limitations
The study did not explore the mechanisms behind the increased U-irEGF concentrations in detail.
Participant Demographics
97 adult patients (49 men and 48 women, aged 28-88 years) with various malignancies.
Statistical Information
P-Value
0.0005
Statistical Significance
p=0.0005
Want to read the original?
Access the complete publication on the publisher's website